中国临床药学杂志2025，Vol.34Issue(3)：199-203,5.DOI:10.19577/j.1007-4406.2025.03.007
低剂量替罗非班治疗急性缺血性卒中的有效性和安全性研究
Efficacy and safety of low-dose tirofiban in the treatment of acute ischemic stroke
摘要
Abstract
AIM To evaluate the efficacy and safety of low-dose tirofiban injection in treating acute ischemic stroke(AIS).METHODS From January 2019 to December 2023,a total of 236 AIS patients treated with early antiplatelet therapy using low-dose tirofiban were collected as the tirofiban group.Additionally,105 AIS patients treated with oral antiplatelet medications for antiplatelet therapy during the same period were selected as the control group.After propensity score matching(PSM),the effectiveness and safety between the 2 groups were compared.RESULTS Following PSM,86 patients were matched in each of 2 groups.Regarding effectiveness,the proportion of patients with a modified Rankin Scale(mRS)score of 0-1 after 3 months of treatment in the tirofiban group was higher than that in the control group(P＜0.05).However,there was no statistically significant difference between the 2 groups in the distribution of mRS scores(0-2 vs＞2)after 3 months of treatment(P＞0.05).There was also no statistically significant difference in National Institutes of Health Stroke Scale(NIHSS)scores between the 2 groups at 72 hours after treatment(P＞0.05).Regarding safety,there were no statistically significant differences between 2 groups in the incidence of various types of intracranial hemorrhage and all-cause mortality within 3 months of treatment(P＞0.05).Additionally,there were no statistically significant differences between the 2 groups in the incidence of thrombocytopenia,positive occult blood tests in the digestive or urinary tract,and extracranial hemorrhage with hemoglobin levels below 100 g·L-1(P＞0.05).CONCLUSION Compared to oral antiplatelet medications,tirofiban demonstrates certain advantages in improving long-term neurological function in patients with AIS,without increasing the risk of bleeding and exhibiting good safety.关键词
急性缺血性卒中/替罗非班/有效性/安全性Key words
acute ischemic stroke/tirofiban/efficacy/safety分类
药学引用本文复制引用
许丹华,史长城,王刚,刘克勤,倪祝美,桑红菲,周永吉,殷聪国..低剂量替罗非班治疗急性缺血性卒中的有效性和安全性研究[J].中国临床药学杂志,2025,34(3):199-203,5.基金项目
浙江省医药卫生科技计划项目(编号2021KY878) （编号2021KY878）
浙江省医药卫生科技计划项目(编号2022KY937) （编号2022KY937）
浙江省杭州市省市共建医学重点学科(编号:浙卫办[2018]2号) （编号:浙卫办[2018]2号）
